Detailed Information
Cited 64 time in 
Cited 68 time in 
Cited 68 time in
Metadata Downloads
Development of a theranostic prodrug for colon cancer therapy by combining ligand-targeted delivery and enzyme-stimulated activation
- Authors
- Sharma, A.[Sharma, A.]; Kim, E.-J.[Kim, E.-J.]; Shi, H.[Shi, H.]; Lee, J.Y.[Lee, J.Y.]; Chung, B.G.[Chung, B.G.]; Kim, J.S.[Kim, J.S.]
- Issue Date
- Feb-2018
- Publisher
- Elsevier Ltd
- Keywords
- Targeted drug delivery; Colon cancer; Theranostic; beta-Galactosidase; Doxorubicin
- Citation
- Biomaterials, v.155, pp.145 - 151
- Indexed
- SCIE
SCOPUS
- Journal Title
- Biomaterials
- Volume
- 155
- Start Page
- 145
- End Page
- 151
- ISSN
- 0142-9612
- Abstract
- The high incidence of colorectal cancer worldwide is currently a major health concern. Although conventional chemotherapy and surgery are effective to some extent, there is always a risk of relapse due to associated side effects, including post-surgical complications and non-discrimination between cancer and normal cells. In this study, we developed a small molecule-based theranostic system, Gal-Dox, which is preferentially taken up by colon cancer cells through receptor-mediated endocytosis. After cancer-specific activation, the active drug Dox (doxorubicin) is released with a fluorescence turn-on response, allowing both drug localization and site of action to be monitored. The therapeutic potency of Gal-Dox was also evaluated, both in vivo and ex vivo, thus illustrating the potential of Gal-Dox as a colorectal cancer theranostic with great specificity. © 2017 Elsevier Ltd
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Graduate School > Chemistry > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.